CYCC - Cyclacel Pharmaceuticals, Inc (NASDAQ Stock)

[Aufan 1983]

Had this one on todays watchlist. They just released the news below and it should make for a nice run.

Only 20.4 million outstanding shares



Cyclacel Begins Phase 2 Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer
0 minutes ago - GlobeNewswire

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) announced today that the company has begun treating patients in a Phase 2, open label, single arm, multicenter clinical trial of sapacitabine (CYC682) in patients with non-small cell lung cancer (NSCLC) who have had one prior chemotherapy. This study builds on the observation of prolonged stable disease of four months or longer experienced by heavily pretreated NSCLC patients involved in two Phase 1 studies of sapacitabine. The multi
Cyclacel Begins Phase 2 Study Of Oral Sapacitabine In Patients With Previously Treated Non-Small Cell Lung Cancer
0 minutes ago - T

[CatFish]

have cycc on my watch list. thanks aufan

[Aufan 1983]

Originally Posted by CATFISH

have cycc on my watch list. thanks aufan

Where did you come up with the Dude dancing? My second question is: Is that you dancing beside your bike?

[BadThad]

Interesting company....how can this be true?

CYCC has little or no debt and, thus, little financial risk.

[Volatile22]

Unreal move today from news on their lung cancer drug. LOD 1.05 HOD 2.74. I grabbed a few at 1.64 sold half at 2.70. Closed at 2.673. Up in afterhours right now 2.73. Hopefully this one kicks up some more tomorrow. Definitely a bullish close.

See news below:

Cyclacel's Seliciclib Found Effective Against Lung Cancer Cell Lines Including K-RAS Mutations

Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) today announced the publication of two peer-reviewed journal articles featuring the company's seliciclib (CYC202 or R-roscovitine) drug candidate, an orally available inhibitor of multiple cyclin-dependent kinases (CDKs). CDKs have been extensively investigated as therapeutic targets in light of their frequent deregulation in lung carcinogenesis. In an article published in Clinical Cancer Research, seliciclib was found to be effective in killing lung cancer cells through a novel apoptotic mechanism or induction of cancer cell suicide. Nearly all lung cancer cell lines against which seliciclib was most effective had Ras-activating mutations. Ras is a family of mutations which make lung cancer cells highly resistant to approved drugs such as those targeting epidermal growth factor receptors (EGFR).

"Drugs that target EGFR, such as cetuximab (Erbitux(R)), erlotinib (Tarceva(R)) and gefitinib (Iressa(R)), are active against non-small cell lung cancer (NSCLC). However Ras family mutations, such as K-RAS and N-RAS, in NSCLC patients are associated with increased resistance to treatment. Approximately 15%-30% of patients with NSCLC harbor Ras mutations and have a poor prognosis," said Professor David Glover, Ph.D., Cyclacel's Chief Scientist. "The data published in Clinical Cancer Research show a high correlation between Ras mutations and sensitivity to seliciclib. Investigating a correlation between clinical outcomes and Ras mutation status in patients from completed seliciclib trials may provide a rationale to select patients for treatment with seliciclib or other CDK inhibitors based on mutational profile. We look forward to unblinding data from our completed Phase 2, randomized, double-blinded APPRAISE trial in patients with pretreated NSCLC during 2010. If seliciclib is found to be effective in patients with Ras-mutant NSCLC, it could address an area of high unmet medical need."

Among 52 cell lines of NSCLC origin tested, 2 (4%) were relatively insensitive to seliciclib, 21 (40%) displayed modest sensitivity and 29 (56%) showed marked sensitivity. Of the 13 lung cancer cell lines which had the highest sensitivity to seliciclib, 12 (92%) had Ras-activating mutations, including K-RAS and N-RAS. However of the 15 lung cancer cell lines which were least sensitive to seliciclib, none had Ras-activating mutations.

The Clinical Cancer Research article entitled, "Targeting the Cyclin E-Cdk-2 Complex Represses Lung Cancer Growth by Triggering Anaphase Catastrophe" reported that inhibition of CDK2 by seliciclib suppressed lung cancer growth both in vitro and in vivo of lung cancer cells addicted to CDK2/cyclin E. As a consequence, lung cancer cells underwent apoptosis or cell suicide by induction of a novel mechanism called anaphase catastrophe, as illustrated in the journal's front cover.

Combining seliciclib with microtubule-targeting agents, such as paclitaxel or docetaxel, was found to be an attractive clinical regimen to consider in patients with lung cancer. The authors also reported studying second-generation CDK inhibitors from Cyclacel with greater potency to seliciclib in terms of inhibiting the growth of lung cancer cells. Citation: Galimberti F., et. al., Clinical Cancer Research, 2010 16:1:109-120.

Seliciclib is currently being evaluated in the APPRAISE trial, a Phase 2b randomized, double-blinded, placebo-controlled trial studying the efficacy and safety of single-agent seliciclib as a third, fourth or fifth line treatment in patients with NSCLC. The trial is using a randomized discontinuation design. The primary endpoint is progression free survival (PFS).

A second peer-reviewed article is entitled "R-roscovitine (seliciclib) affects CLL cells more strongly than combinations of fludarabine or cladribine with cyclophosphamide: Inhibition of CDK7 sensitizes leukemic cells to caspase-dependent apoptosis". While CDK inhibitors are known to have clinical activity against B-cell Chronic Lymphocytic Leukemia (B-CLL) cells, this publication directly compares the activity of seliciclib with commonly used therapeutic options, such as the combination of fludarabine and cyclophosphamide. In these ex vivo studies, seliciclib was compared to fludarabine and cladribine given in combination with cyclophosphamide. Seliciclib was found to be the most effective at inducing apoptosis or programmed cell death in malignant B-CLL cells while resulting in significantly less apoptosis induction in "normal" peripheral blood mononuclear cells, suggesting the largest therapeutic window among the treatments studied. Citation: Rogalinska M., et. al., Journal of Cell Biochemistry, 2010 Jan 1, 109:1:217-235.

[fz4fun]

Nice Play Vol--currently trading at 3.03 post market and looking strong for tomorrow open
Good luck and glad you held some shares-might keep going up for you.

I am out of powder right now so just watching the move.


Dancing bananas for you

[Volatile22]

Originally Posted by fz4fun

Nice Play Vol--currently trading at 3.03 post market and looking strong for tomorrow open
Good luck and glad you held some shares-might keep going up for you.

I am out of powder right now so just watching the move.


Dancing bananas for you

Thanks FZ, Im still holding the second half of my shares. Its just around 3.70 right now. This is one crazy play. I thought I was pushing my luck with my 1.64 buy.

[greencat]

CYCC is holding 50% of the big candle. It has now broke a short term trendline. I very well could be ready for another leg up.

CYCC Chart

[greencat]

CYCC lloks like its ready to make a move out of this consolidtion pattern...

CYCC Chart
[/QUOTE]